INCYTE WKN: 896133 ISIN: US45337C1027 Kürzel: INCY Forum: Aktien Thema: Hauptdiskussion

Abgeprallt und neuer Versuch jetzt sieht es ganz gut aus wenn der s&p mal bissl hoch geht ballert das Teil auch

Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs https://www.businesswire.com/news/home/20220208005340/en/Incyte-Reports-2021-Fourth-Quarter-and-Year-End-Financial-Results-and-Provides-2022-Financial-Guidance-and-Updates-on-Key-Clinical-Programs • Total product and royalty revenues of $813 million (+20%) in Q4’21 and $2.891 billion (+17%) in FY’21 • Jakafi® (ruxolitinib) net product revenues of $592 million (+15%) in Q4’21 and $2.135 billion (+10%) in FY’21; Jakafi guidance range of $2.3 to $2.4 billion for 2022 • Successful U.S. launch of Opzelura™ (ruxolitinib) cream in atopic dermatitis with nearly 19,000 patients treated from launch (October 11th) through the end of the year • Vitiligo is the next substantial growth opportunity for ruxolitinib cream – under Priority Review in the U.S. and under review in Europe

Die Zahlen sind wohl nicht gut ankommen

Bessere Zahlen als erwartet und das Teil geht baden 😆 aktuell läuft der biotech Sektor gar nicht... wann dreht das mal wieder wahrscheinlich wenn die indizes mal abschmieren

👁👁

Laut Lynx, könnte der Boden gefunden worden sein. Bin am überlegen 🤔

Könnte jetzt dynamisch hoch gehen 🤪

Ist der Boden gefunden?

Alter in dem Umfeld steigt das ding🤩

Erwartungen geschlagen aber den Markt enttäuscht...seltsame Sache hier

https://www.investing.com/news/stock-market-news/incyte-earnings-revenue-beat-in-q3-2663920 Incyte Earnings, Revenue Beat in Q3

Lebt die Aktie wieder? News?

Danke für die Info. Ich finde den Abverkauf aber echt heftig.

https://www.businesswire.com/news/home/20210922005863/en/Incyte-Announces-FDA-Approval-of-Jakafi%C2%AE-ruxolitinib-for-Treatment-of-Chronic-Graft-Versus-Host-Disease-GVHD

Hey DAKo, hängt sicher mit der gleichzeitigen Warnung zusammen: Incyte trades lower on safety warning in FDA approval for Opzelura https://seekingalpha.com/news/3742134-incyte-trades-lower-on-safety-warning-in-fda-approval-for-opzelura • Despite the FDA approval granted for Opzelura cream as a treatment of mild to moderate atopic dermatitis (AD), Incyte Corporation (NASDAQ:INCY) has lost ~2.5% in the pre-market after the regulator added a Boxed Warning to flag its safety concerns. • Opzelura is the first and only topical formulation of JAK (Janus kinase) inhibitors approved in the U.S., the company said. The treatment comes with the FDA’s JAK-class warning to indicate the risks of severe infections, higher risk of heart attack, stroke, etc. • The boxed warnings could hurt the long-term sales opportunity and cause a near-term reaction on company shares, Reuters reported quoting RBC analyst Brian Abraham. • The warning on Opzelura could reduce its uptake by about 30% in patients with the mild form of the disease, in particular, Abraham argues, citing a physician survey carried out by the firm. • The renewed safety concerns on the JAK class of drugs pressured AbbVie (NYSE:ABBV) early this month. The company manufactures JAK inhibitor Rinvoq (upadacitinib) indicated for rheumatoid arthritis in adults.